Description
Looking for adults with advanced lung cancer who have had platinum chemotherapy and immunotherapy before. This study compares usual medicine with or without a new medicine called cemiplimab.
Overview
Participants in this study will be randomly selected to receive either the investigational drug cemiplimab in addition to the usual non-small cell lung cancer treatment infusion or just the usual treatment alone.
What we're hoping for
We are studying if adding a new medicine called cemiplimab to the usual medicines, docetaxel and ramucirumab, can help adults with advanced lung cancer live longer.
Additional Information
ClinicalTrials.gov Identifier: NCT06616584